Celularity (NASDAQ:CELU) Announces Quarterly Earnings Results

Celularity (NASDAQ:CELU) announced its earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $5.43 million for the quarter.

Celularity Stock Performance

Shares of CELU stock opened at $1.02 on Thursday. Celularity has a fifty-two week low of $0.56 and a fifty-two week high of $2.55. The firm has a market capitalization of $33.10 million, a PE ratio of -0.60 and a beta of 0.77. The stock’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $1.03.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Celularity

A hedge fund recently bought a new position in Celularity stock. C V Starr & Co. Inc. purchased a new position in shares of Celularity, Inc. (NASDAQ:CELU) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises about 0.8% of C V Starr & Co. Inc.’s holdings, making the stock its 4th biggest holding. C V Starr & Co. Inc. owned 2.64% of Celularity at the end of the most recent reporting period. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.